Brind.

The FDA approved Amtagvi, a T cell therapy developed by Iovance Biotherapeutics.

8 reports, 4 independent Updated Sep 22

Gone quiet

Reports: 8
Developments: 1
Repetition: 88%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

The FDA approved Amtagvi, a T cell therapy developed by Iovance Biotherapeutics.

Who's involved

What this event is mainly about

FDA Iovance Biotherapeutics

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Iovance Biotherapeutics
American biopharmaceutical startup

Nothing else this week.

Coverage

Newest first; wire copies grouped

Sep 22themarketsdaily.com
Aug 6ibtimes.com.au
Aug 1yahoo.com
Jul 25GlobeNewswireIovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025 SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Io
Jul 14GlobeNewswireReal-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma 61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 20
Jun 24Unknown outlet

2 more outlets ran the same wire story

Aug 6insidermonkey.com
Aug 6yahoo.com